Search company, investor...

Reacta Biotech

Founded Year



Seed VC | Alive

Total Raised


Last Raised

$4.03M | 1 yr ago

About Reacta Biotech

Reacta Biotech operates as a biotechnology company that produces diagnostic kits for food allergy.

Headquarters Location

Forge House Church End Barley Royston

Hertfordshire, England, SG8 8JN,

United Kingdom

Missing: Reacta Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Reacta Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Reacta Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Reacta Biotech is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,560 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,534 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Health IT

7,901 items

Reacta Biotech Patents

Reacta Biotech has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Food allergies, Allergology, Polysaccharides, Food additives, Sugar substitutes


Application Date


Grant Date



Related Topics

Food allergies, Allergology, Polysaccharides, Food additives, Sugar substitutes



Latest Reacta Biotech News

Praetura Ventures leads £2.9m investment in food allergy diagnostic firm

Sep 13, 2021

Dr Paul Abrahams, CEO of Reacta Praetura Ventures, the Manchester-based VC firm, has led a £2.9m funding round to support a business that is on course to transform the food allergy diagnostics market. Reacta Biotech (Reacta), which is based in Deeside, North Wales, produces clinical diagnostics kits for food allergy testing. The business improves the efficiency, accuracy and safety of food allergy testing by producing pharmaceutical grade Oral Food Challenges (OFCs), the gold standard test for diagnosing food allergies. In the latest funding round, £1.5m came from Praetura Ventures, the venture capital fund manager that targets early-stage businesses in high-growth sectors. Having made an initial seed investment in 2019, the Development Bank of Wales will invest a further £1m in equity funding. Other investors in the funding round include venture capitalist Jon Moulton’s family office, Perscitus and  Reacta’s management team. The transaction was brokered by Reacta’s long-term advisers, Acceleris Capital, who have previously raised £4m for the company since it was founded. The business will use the funding to scale up the manufacture of its current product range including peanut, egg and milk OFCs and to extend its product portfolio. Related Articles Dr Paul Abrahams, CEO of Reacta, said: “It’s been a landmark year for Reacta, and we continue to go from strength-to-strength as a business, developing new diagnostic products and expanding our capabilities. “The number of people experiencing food allergies is increasing, so it’s vital that technologies to accurately and safely test for allergies are developed. “We’re committed to providing excellence in the development of a suite of OFC products, and revolutionising the way food allergies are diagnosed worldwide.” Praetura Ventures has previously invested in healthcare businesses including innovative drug ‘switching’ company Maxwellia, Dr Fertility and Ostara Biomedical. The firm recently appointed four industry heavyweights as operational partners to bring significant experience to support the founders. “The firm’s investment in Reacta was led by investment director Louise Chapman and director Dr Andy Round. Dr Andy Round added: “It’s great to be backing a business which is on track to have a significant and positive impact on society as well as returning significant funds for our investors. “We look forward to supporting the team on the clinical contacts and customer side, as well as working with them on the strategy and marketing.” Previous Article

Reacta Biotech Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Reacta Biotech Rank

Reacta Biotech Frequently Asked Questions (FAQ)

  • When was Reacta Biotech founded?

    Reacta Biotech was founded in 2014.

  • Where is Reacta Biotech's headquarters?

    Reacta Biotech's headquarters is located at Forge House Church End Barley Royston, Hertfordshire.

  • What is Reacta Biotech's latest funding round?

    Reacta Biotech's latest funding round is Seed VC.

  • How much did Reacta Biotech raise?

    Reacta Biotech raised a total of $5.59M.

  • Who are the investors of Reacta Biotech?

    Investors of Reacta Biotech include Development Bank of Wales, Praetura Ventures, acceleris and Moulton Goodies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.